These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

35 related articles for article (PubMed ID: 19221368)

  • 1. Progress report of a cross-organ and biomarker-based basket-type clinical trial: BELIEVE Trial.
    Ando Y; Shimoi T; Sunami K; Okita N; Nakamura K; Shibata T; Fujiwara Y; Yamamoto N
    Cancer Sci; 2024 Feb; 115(2):555-563. PubMed ID: 38041215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence Underlying Recommendations and Payments from Industry to Authors of the National Comprehensive Cancer Network Guidelines.
    Liu X; Tang LL; Mao YP; Liu Q; Sun Y; Chen L; Lin JC; Ma J
    Oncologist; 2019 Apr; 24(4):498-504. PubMed ID: 30459237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study.
    Wagner J; Marquart J; Ruby J; Lammers A; Mailankody S; Kaestner V; Prasad V
    BMJ; 2018 Mar; 360():k668. PubMed ID: 29514787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Off-label therapy: current problems from the perspective of the Pharmaceutical Commission of the German Medical Profession].
    Janzen RW; Ludwig WD;
    Z Rheumatol; 2012 Feb; 71(2):108-10, 112-8. PubMed ID: 22370801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The notorious "drug lag" for oncology drugs in Japan.
    Yonemori K; Hirakawa A; Ando M; Hirata T; Yunokawa M; Shimizu C; Katsumata N; Tamura K; Fujiwara Y
    Invest New Drugs; 2011 Aug; 29(4):706-12. PubMed ID: 21286780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Off-label prescribing: a call for heightened professional and government oversight.
    Dresser R; Frader J
    J Law Med Ethics; 2009; 37(3):476-86, 396. PubMed ID: 19723258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlling off-label medication use.
    Gillick MR
    Ann Intern Med; 2009 Mar; 150(5):344-7. PubMed ID: 19221367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating off-label uses of anticancer drugs: time for a change.
    Sox HC
    Ann Intern Med; 2009 Mar; 150(5):353-4. PubMed ID: 19221369
    [No Abstract]   [Full Text] [Related]  

  • 9. Systematic review: reliability of compendia methods for off-label oncology indications.
    Abernethy AP; Raman G; Balk EM; Hammond JM; Orlando LA; Wheeler JL; Lau J; McCrory DC
    Ann Intern Med; 2009 Mar; 150(5):336-43. PubMed ID: 19221366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Off-label cancer drug compendia found outdated and incomplete.
    Mitka M
    JAMA; 2009 Apr; 301(16):1645-6. PubMed ID: 19383947
    [No Abstract]   [Full Text] [Related]  

  • 11. Compendia and anticancer therapy under Medicare.
    Tillman K; Burton B; Jacques LB; Phurrough SE
    Ann Intern Med; 2009 Mar; 150(5):348-50. PubMed ID: 19221368
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.